These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33277363)

  • 1. An inducible glycogen synthase-1 knockout halts but does not reverse Lafora disease progression in mice.
    Nitschke S; Chown EE; Zhao X; Gabrielian S; Petković S; Guisso DR; Perri AM; Wang P; Ahonen S; Nitschke F; Minassian BA
    J Biol Chem; 2021; 296():100150. PubMed ID: 33277363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease.
    Ahonen S; Nitschke S; Grossman TR; Kordasiewicz H; Wang P; Zhao X; Guisso DR; Kasiri S; Nitschke F; Minassian BA
    Brain; 2021 Nov; 144(10):2985-2993. PubMed ID: 33993268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of glycogen synthesis as a treatment for Lafora disease: Establishing the window of opportunity.
    Varea O; Duran J; Aguilera M; Prats N; Guinovart JJ
    Neurobiol Dis; 2021 Jan; 147():105173. PubMed ID: 33171226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laforin prevents stress-induced polyglucosan body formation and Lafora disease progression in neurons.
    Wang Y; Ma K; Wang P; Baba O; Zhang H; Parent JM; Zheng P; Liu Y; Minassian BA; Liu Y
    Mol Neurobiol; 2013 Aug; 48(1):49-61. PubMed ID: 23546741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic Dissociation: Robust Lafora Body Accumulation in Malin KO Mice Without Observable Changes in Home-Cage Behavior.
    Krishnan V; Wu J; Mazumder AG; Kamen JL; Schirmer C; Adhyapak N; Bass JS; Lee SC; Maheshwari A; Molinaro G; Gibson JR; Huber KM; Minassian BA
    J Comp Neurol; 2024 Jul; 532(7):e25660. PubMed ID: 39039998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trehalose Ameliorates Seizure Susceptibility in Lafora Disease Mouse Models by Suppressing Neuroinflammation and Endoplasmic Reticulum Stress.
    Sinha P; Verma B; Ganesh S
    Mol Neurobiol; 2021 Mar; 58(3):1088-1101. PubMed ID: 33094475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycogen hyperphosphorylation underlies lafora body formation.
    Turnbull J; Wang P; Girard JM; Ruggieri A; Wang TJ; Draginov AG; Kameka AP; Pencea N; Zhao X; Ackerley CA; Minassian BA
    Ann Neurol; 2010 Dec; 68(6):925-33. PubMed ID: 21077101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Gys1 with AAV-SaCas9 Decreases Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models.
    Gumusgoz E; Guisso DR; Kasiri S; Wu J; Dear M; Verhalen B; Nitschke S; Mitra S; Nitschke F; Minassian BA
    Neurotherapeutics; 2021 Apr; 18(2):1414-1425. PubMed ID: 33830476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease.
    Tiberia E; Turnbull J; Wang T; Ruggieri A; Zhao XC; Pencea N; Israelian J; Wang Y; Ackerley CA; Wang P; Liu Y; Minassian BA
    J Biol Chem; 2012 Jul; 287(30):25650-9. PubMed ID: 22669944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gys1 Antisense Therapy Prevents Disease-Driving Aggregates and Epileptiform Discharges in a Lafora Disease Mouse Model.
    Donohue KJ; Fitzsimmons B; Bruntz RC; Markussen KH; Young LEA; Clarke HA; Coburn PT; Griffith LE; Sanders W; Klier J; Burke SN; Maurer AP; Minassian BA; Sun RC; Kordasiewisz HB; Gentry MS
    Neurotherapeutics; 2023 Oct; 20(6):1808-1819. PubMed ID: 37700152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting glycogen synthesis prevents Lafora disease in a mouse model.
    Pederson BA; Turnbull J; Epp JR; Weaver SA; Zhao X; Pencea N; Roach PJ; Frankland PW; Ackerley CA; Minassian BA
    Ann Neurol; 2013 Aug; 74(2):297-300. PubMed ID: 23913475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscle glycogen remodeling and glycogen phosphate metabolism following exhaustive exercise of wild type and laforin knockout mice.
    Irimia JM; Tagliabracci VS; Meyer CM; Segvich DM; DePaoli-Roach AA; Roach PJ
    J Biol Chem; 2015 Sep; 290(37):22686-98. PubMed ID: 26216881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ontogeny of Lafora bodies and neurocytoskeleton changes in Laforin-deficient mice.
    Machado-Salas J; Avila-Costa MR; Guevara P; Guevara J; Durón RM; Bai D; Tanaka M; Yamakawa K; Delgado-Escueta AV
    Exp Neurol; 2012 Jul; 236(1):131-40. PubMed ID: 22542948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency.
    Nitschke S; Sullivan MA; Mitra S; Marchioni CR; Lee JPY; Smith BH; Ahonen S; Wu J; Chown EE; Wang P; Petković S; Zhao X; DiGiovanni LF; Perri AM; Israelian L; Grossman TR; Kordasiewicz H; Vilaplana F; Iwai K; Nitschke F; Minassian BA
    Brain; 2022 Jul; 145(7):2361-2377. PubMed ID: 35084461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease.
    Nitschke F; Sullivan MA; Wang P; Zhao X; Chown EE; Perri AM; Israelian L; Juana-López L; Bovolenta P; Rodríguez de Córdoba S; Steup M; Minassian BA
    EMBO Mol Med; 2017 Jul; 9(7):906-917. PubMed ID: 28536304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
    DePaoli-Roach AA; Tagliabracci VS; Segvich DM; Meyer CM; Irimia JM; Roach PJ
    J Biol Chem; 2010 Aug; 285(33):25372-81. PubMed ID: 20538597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intracerebroventricular administration of alglucosidase alfa in two mouse models of Lafora disease: Relevance for clinical practice.
    Zafra-Puerta L; Colpaert M; Iglesias-Cabeza N; Burgos DF; Sánchez-Martín G; Gentry MS; Sánchez MP; Serratosa JM
    Epilepsy Res; 2024 Feb; 200():107317. PubMed ID: 38341935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ppp1r3d deficiency preferentially inhibits neuronal and cardiac Lafora body formation in a mouse model of the fatal epilepsy Lafora disease.
    Israelian L; Nitschke S; Wang P; Zhao X; Perri AM; Lee JPY; Verhalen B; Nitschke F; Minassian BA
    J Neurochem; 2021 Jun; 157(6):1897-1910. PubMed ID: 32892347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation.
    Fernández-Sánchez ME; Criado-García O; Heath KE; García-Fojeda B; Medraño-Fernández I; Gomez-Garre P; Sanz P; Serratosa JM; Rodríguez de Córdoba S
    Hum Mol Genet; 2003 Dec; 12(23):3161-71. PubMed ID: 14532330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin.
    Vernia S; Rubio T; Heredia M; Rodríguez de Córdoba S; Sanz P
    PLoS One; 2009 Jun; 4(6):e5907. PubMed ID: 19529779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.